Ocugen: OCU410 shows 46% GA lesion reduction in Phase 2; Phase 1 EZ loss 60% slower

Ocugen, Inc.

Phase 2 preliminary 12-month data (N=23) shows 46% GA lesion growth reduction vs control (p=0.015); medium dose 54% (p=0.02), high dose 36% (p=0.05).
Subgroup with baseline ≥7.5 mm² (N=14) demonstrated 57% reduction in lesion size vs control.
Phase 1 (N=7 evaluable) shows 60% slower ellipsoid zone loss in treated eyes vs untreated fellow eyes at 12 months.
No OCU410-related serious adverse events reported across Phase 1 and Phase 2; no endophthalmitis, retinal detachment, or vasculitis.
Company plans full Phase 2 data later Q1 2026, initiate Phase 3 in 2026, and BLA filing in 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.